Kala Bio (KALA) Operating Income (2016 - 2026)
Kala Bio (KALA) posted Operating Income of -$1.8 million for Q1 2026, up 82.38% sequentially from -$10.2 million in Q4 2025, and up 83.11% YoY from -$984108.2 in Q1 2025.
Kala Bio (KALA) Operating Income (2016 - 2026) Analysis & Trends
Kala Bio has reported Operating Income for 11 years, with the latest figure at -$1.8 million in Q1 2026.
- Quarterly Operating Income rose 83.11% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.3 million (up 23.73% YoY) and the FY2025 annual result came in at -$39.2 million, up 4.45% from the prior year.
- Operating Income grew to -$1.8 million in Q1 2026 per KALA's latest filing, from -$10.2 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.8 million in Q1 2026 and troughed at -$30.9 million in Q1 2022.
- A 5-year average of -$12.0 million and a median of -$10.2 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2025 and 2026: Operating Income dropped 14.82% in 2025, then jumped 83.11% in 2026.
- Over 5 years, Operating Income stood at -$10.3 million in 2022, then climbed by 6.17% to -$9.6 million in 2023, then climbed by 1.66% to -$9.5 million in 2024, then fell by 8.1% to -$10.2 million in 2025, then soared by 82.38% to -$1.8 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.8 million, -$10.2 million, and -$7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -10.23 Mn |
| Sep 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -11.03 Mn |
| Mar 31, 2025 | -10.67 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -9.99 Mn |
| Jun 30, 2024 | -9.61 Mn |
| Mar 31, 2024 | -11.93 Mn |
| Dec 31, 2023 | -9.62 Mn |
| Sep 30, 2023 | -8.76 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -11.68 Mn |
| Dec 31, 2022 | -10.25 Mn |
| Sep 30, 2022 | -14.57 Mn |
| Jun 30, 2022 | -25.97 Mn |
| Mar 31, 2022 | -30.91 Mn |
| Dec 31, 2021 | -46.82 Mn |
| Sep 30, 2021 | -26.07 Mn |
| Jun 30, 2021 | -29.05 Mn |